Key facts
- It has raised $1.3M; the latest was Early Stage VC ($1.2M) in Jul 2025.
- Notable investors include Hub71, Plus Venture Capital, 25madison, Annex Investments (UAE).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ovasave
- ·The full record, as it builds
Funding rounds
No funding rounds for Ovasave are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ovasave
Provider of fertility and hormonal health services intended for accessible reproductive care. The company's platform offers at-home testing for ovarian reserve, hormone levels, and sexually transmitted infections, along with expert consultations to support personalized treatment decisions and facilitate convenient sample collection, secure result access, and professional guidance, enabling individuals to monitor their reproductive health, navigate fertility planning, and make informed medical choices with ease.
- Sector
- Healthcare
- HQ
- Abu Dhabi, United Arab Emirates
- Founded
- 2022
- Employees
- 5
- Website
- ovasave.com/
- Ownership
- Privately Held (backing)
Ovasave doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ovasave shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ovasave in its N-PORT filings yet. We sweep new filings monthly.